Reducing the use of sedative medication in aged care facilities: Implementation of the ‘RedUSe’ Project into everyday practice

Final Report 2017
Executive Summary
© Wicking Dementia Research & Education Centre, University of Tasmania, 2017

Hobart, Tasmania, Wicking Dementia Research and Education Centre, University of Tasmania.
March 2017
Correspondence: Dr Juani ta Westbury, Senior Lecturer Dementia Studies,
Wicking Dementia Research and Education Centre, Private Bag 143, Hobart, Tasmania, Australia 7001.
juanita.westbury@utas.edu.au

Acknowledgements

The authors would like to acknowledge the contribution of the funding body supporting this implementation project, namely the Australian Government Department of Health, Dementia and Aged Care Service Fund (formally known as the Aged Care Service Improvement and Healthy Ageing Fund).

We also wish to acknowledge the many people involved in the implementation of the RedUSe project.

Investigators: Dr Juanita Westbury, Professor Gregory Peterson, Peter Gee, Dr Tristan Ling, Dr Ivan Bindoff, Dr Lisa Clinnick, Daniel Hoyle, Friso Schotel, Donnamay Brown and Katherine Franks.

RedUSe administration team: Helen Morrongiello, Helen Bridgman, Janita Groombridge, Caroline Flood, Ana Gencic, and Angus McIlhenny.

RedUSe project pharmacists: Hilary Edwards, Sue Edwards, Claire Lovell, Helen Benson, Amanda Sanburg, Dr Andrew Stafford, Adam Phillips and Rosemary Allin.

Key Stakeholders, Collaborators and Steering group: Kay Richards (LASA), Darren Mathewson (ACSA), Margaret Ryan (Bupa Care), Ania Karzek (SCC), Joey Calandra (PSA), Jeff Elliott (NPS MedicineWise), Debra Rowett (DATIS), Margaret Bird (COTA), Danijela Hlis (AA), Dr Lisa Clinnick (Australian Catholic University) and Dr Henry Konopnicki.

And finally we wish to acknowledge the staff and residents at all 150 participating Residential Aged Care Facilities, their pharmacists, supply community pharmacies and the GPs who provide medical care to their residents.
Executive Summary

Antipsychotics were developed to treat serious mental health conditions, such as schizophrenia. In older people, however, these agents are now mostly prescribed to manage behavioural and psychological symptoms of dementia (BPSD), including aggression, delusions and calling out. Their effectiveness to treat these symptoms is modest, yet the risks associated with use can be severe, ranging from confusion and falls, to stroke and death. Similarly, benzodiazepines are prescribed in older people to treat sleep disturbance, anxiety and agitation. Benzodiazepines can be effective in the short-term, but then tolerance develops, and use is associated with over-sedation and confusion, falls, and the risk of dependence.

In view of their modest benefits, accompanied by significant risks, national and international guidelines recommend that both medication classes should be prescribed judiciously when anxiety, sleep disturbance and/or BPSD cause significant distress, or pose a safety risk. When prescribed, they should be monitored regularly for effectiveness and adverse effects, whilst using the lowest effective dose for the shortest period of time.

Inappropriate use of antipsychotic and benzodiazepine agents has been recognised as an issue in Residential Aged Care Facilities (RACFs) in Australia for several decades, resulting in Federal and State government inquiries, media attention and the release of a succession of professional guidelines. However, antipsychotic and benzodiazepine use continues to be high in this setting, with many residents often taking these medications inappropriately, for extended periods.

The RedUSe (Reducing Use of Sedatives) project expansion was funded in 2013 by the Department of Health through the ‘Dementia and Aged Care Service Fund’. The overarching aim of RedUSe is to promote the appropriate use of antipsychotics and benzodiazepines (collectively termed ‘sedatives’) in RACFs. The project was first trialled successfully in a 2008 study involving 25 Tasmanian RACFs. The federally-funded expansion involved 150 RACFs, distributed throughout Australia during 2014-16.

RedUSe is a multi-strategic, interdisciplinary, structured initiative, which employs several approaches specifically targeted to improve sedative use. During the 6-month project, each RACF’s sedative medication use is audited at baseline, 3 months and 6 months, using a customised e-Health tool. The audit results are then presented to nursing staff and carers during two educational sessions. Following this education, all residents taking sedative medication are reviewed, in an interdisciplinary process involving a pharmacist, a champion nurse at each facility and the resident’s GP or nurse prescriber. The diagram below illustrates the main RedUSe strategies:

The RedUSe project was enhanced for expansion by developing an interactive training program for nursing staff designed to challenge positive beliefs around sedative use. Training was also delivered on the risks and benefits associated with sedative use in older people, and concise guidelines were provided. The sedative review process was automated. Nurse input was crucial and professional roles clearly defined. The ‘champion nurse’ role was created for an expert peer to promote and model ‘good practice’. Finally, academic detailing was delivered externally, by trained detailers from NPS MedicineWise and DATIS, to inform and engage GPs.
Strong demand to participate in RedUSe was generated after the two Australian peak aged care organisations, LASA and ACSA, promoted the project in print and on-line newsletters, resulting in expression of interest forms from over 300 RACFs. Our full target of 150 RACFs was recruited by September 2015.

**At baseline we found that over a third of residents (37%) were taking a sedative medication daily.** Specifically, 22% were taking an antipsychotic and 22% of residents were taking a benzodiazepine. With ‘prn’ or ‘as required’ prescriptions included, over half of all RACF residents (54%) were prescribed a sedative agent.

Throughout RedUSe, antipsychotic and benzodiazepine use in each of the 150 RACFs was measured at baseline and then re-measured at 3 and 6 months, with 12,153 residents, on average, included at each time point. **Overall, a significant reduction was found in antipsychotic and benzodiazepine use.** A 13% relative reduction was observed in the prevalence of antipsychotics from baseline to 6-months (from 22% to 19% of residents). The reduction in benzodiazepine prevalence was higher; at 21% (from 22% to 17.5%).

**The reduction was also sustained over time:** Over 80% of antipsychotic agents, and 90% of benzodiazepines ceased or reduced at 3 months, remained reduced when residents were re-checked at 6-months. A quarter of residents who had their sedative dose reduced at 3-months, were ceased altogether by the 6-month audit. The graph below shows sedative usage rates averaged across all 150 RACFs from baseline to 6 months:

![Sedative usage rates graph](image)

**A total of 115 RACFs (77%) reduced their antipsychotic use prevalence, with 127 of the RACFs (85%) reducing benzodiazepine use.** Out of 150 RACFs, two-thirds of the facilities (66%), reduced both antipsychotic and benzodiazepine prescribing rates. The response rate across the RedUSe expansion is shown below:

![Response rate graph](image)

Substitution to sedative antidepressants, or greater ‘prn’ use of these agents, did not occur as the overall use of these agents declined from baseline to 6-months.
A recent study in N.S.W reported that only 4% of residents taking sedative agents have their medication reduced, or ceased, over a 6-month period. In the RedUSe project RACFs, 41% of all residents taking sedative medication had doses reduced or ceased altogether. This means that the proportion of sedative dose reductions in RedUSe RACFs was effectively ten times higher than the rate observed in routine practice.

When all 2195 residents taking antipsychotics at baseline were tracked over the 6-month project, 483 residents (22%) were ceased off antipsychotics outright, and a further 354 residents (16%) had their dose reduced. The impact on benzodiazepine use was more pronounced. Of 2247 residents taking benzodiazepines at baseline, 576 (26%) were ceased off these agents completely, with 332 of these residents (15%) having their dose reduced.

The education provided to the aged care sector as a result of this project was substantial. Over 2500 nursing staff and carers attended RACF RedUSe educational sessions, with 76 pharmacists trained to deliver this content. Using a validated quiz, we found that the psychotropic knowledge of all levels of nursing and care staff significantly improved. Staff also rated the training highly, with over 85% ranking the training as ‘very good’ or ‘excellent’. Participants particularly valued the opportunity to discuss the use of sedative medications in their residents and many wanted to learn more about medications and their side effects, along with non-pharmacological approaches.

Although several interventions have been designed and trialled to reduce sedative medication use in RACFs, few have evaluated the clinical impact of such a program on the residents themselves. The expansion of the RedUSe project offered an ideal opportunity to do this and also establish if the project impacted upon staff satisfaction.

Using a sample of over 200 sedative users from 27 RACFs, we found there were no significant increases in behavioural symptoms for sedative reducers, contrary to expectations. In fact, antipsychotic reducers saw improvements in some behaviours, specifically agitation, whilst the non-reducers had worsening behaviour. Reducing benzodiazepine use was shown to increase the residents’ ability to perform activities of daily living. Finally, participating in the RedUSe project, with ensuing sedative reduction, did not adversely affect job satisfaction of nursing staff.

A comprehensive health economic analysis was not possible due to the stipulation that control groups were not permitted. However, based on data from the clinical impact study, with assumptions of implementation/operation costs and extrapolated nationally, the RedUSe program is expected to provide overall cost savings in the order of $3.9m per annum, primarily driven through reduced hospitalisations in patients who had their sedative medications reduced and savings from reduced usage of antipsychotics.

In conclusion, the national expansion of RedUSe proved an effective intervention to significantly reduce RACF antipsychotic and benzodiazepine use, with high degrees of staff, pharmacist and GP satisfaction.

Key Recommendations

- The RedUSe program should be made available to all Australian RACFs
- The RedUSe program should be offered as a funded quality improvement strategy by pharmacists – with an appropriate remuneration structure developed to support its implementation
- RACF prevalence of antipsychotic and benzodiazepine use should be National Quality Indicators
- Training for health professionals on non-pharmacological management of BPSD should be enhanced
- A comprehensive investigation of the long-term clinical outcomes from reducing RACF sedative use is required, along with a full economic analysis.